Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
Stefan Müller-Lissner,I. Fumagalli,K. D. Bardhan,Fabio Pace,E. Pecher,Brigitte Nault,P. Rüegg +6 more
TLDR
To investigate the efficacy and safety of tegaserod, a novel 5‐HT4 receptor partial agonist, in a randomized, double‐blind, placebo‐controlled, 12‐week treatment, multicentre study.Abstract:
Aim:
To investigate the efficacy and safety of tegaserod, a novel 5-HT4 receptor partial agonist, in a randomized, double-blind, placebo-controlled, 12-week treatment, multicentre study.
Methods:
Eight hundred and eighty-one patients with irritable bowel syndrome, characterized by abdominal pain, bloating and constipation, received tegaserod, 2 mg b.d. or 6 mg b.d., or placebo for 12 weeks.
Results:
Tegaserod, 2 mg b.d. and 6 mg b.d., showed a statistically significant relief of overall irritable bowel syndrome symptoms, measured by a weekly, self-administered questionnaire. At end-point, treatment differences from placebo were 12.7% and 11.8% for 2 mg b.d. and 6 mg b.d., respectively. The effect of tegaserod was noted as early as week 1, and was sustained over the 12-week treatment period. Individual irritable bowel syndrome symptoms assessed daily also showed a statistically significant improvement of abdominal discomfort/pain, number of bowel movements and stool consistency, and a favourable trend for reducing days with significant bloating. Adverse events were similar in all groups, with transient diarrhoea being the only adverse event seen more frequently with tegaserod than placebo.
Conclusions:
Based upon the results of this study, tegaserod offers rapid and sustained relief of the abdominal pain and constipation associated with irritable bowel syndrome. Tegaserod is also well tolerated.read more
Citations
More filters
Journal ArticleDOI
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles
Liam O'Mahony,Jane McCarthy,Peter Kelly,George J Hurley,Fangyi Luo,Ker-Sang Chen,Gerald C. O'Sullivan,Barry Kiely,J. Kevin Collins,Fergus Shanahan,Eamonn Martin Quigley +10 more
TL;DR: B infantis 35624 alleviates symptoms in IBS; this symptomatic response was associated with normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for this organism, in this disorder.
Journal ArticleDOI
The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders
Michael D. Gershon,Jan Tack +1 more
TL;DR: Serotonin is an important gastrointestinal signaling molecule as mentioned in this paper, which is used by enterochromaffin (EC) cells to activate intrinsic and extrinsic primary afferent neurons to initiate peristaltic and secretory reflexes and transmit information to the central nervous system.
Journal ArticleDOI
Studying sex and gender differences in pain and analgesia: a consensus report
Joel D. Greenspan,Rebecca M. Craft,Linda LeResche,Lars Arendt-Nielsen,Karen J. Berkley,Roger B. Fillingim,Michael S. Gold,Anita Holdcroft,Stefan Lautenbacher,Emeran A. Mayer,Jeffrey S. Mogil,Anne Z. Murphy,Richard J. Traub +12 more
TL;DR: In this article, members of the Sex, Gender and Pain Special Interest Group of the International Association for the Study of Pain met to discuss the following: (1) what is known about sex and gender differences in pain and analgesia; (2) what are the "best practice" guidelines for pain research with respect to sex this article.
Consensus report Studying sex and gender differences in pain and analgesia: A consensus report
Joel D. Greenspan,Rebecca M. Craft,Linda LeResche,Lars Arendt-Nielsen,Karen J. Berkley,Roger B. Fillingim,Michael S. Gold,Anita Holdcroft,Stefan Lautenbacher,Emeran A. Mayer,Jeffrey S. Mogil,Anne Z. Murphy,Richard J. Traub +12 more
TL;DR: This document is intended to serve as a utilitarian and thought-provoking guide for future research on sex and gender differences in pain and analgesia, both for those currently working in this field as well as those still wondering, "Do I really need to study females?"
Journal ArticleDOI
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Peter J. Whorwell,Linda Altringer,Jorge G. Morel,Yvonne Bond,Duane Larry Charbonneau,Liam O'Mahony,Barry Kiely,Fergus Shanahan,Eamonn Martin Quigley +8 more
TL;DR: B. infantis 35624 at a dose of 1 × 108 cfu was significantly superior to placebo and all other bifidobacterium doses for the primary efficacy variable of abdominal pain as well as the composite score and scores for bloating, bowel dysfunction, incomplete evacuation, straining, and the passage of gas at the end of the 4-wk study.
References
More filters
Journal ArticleDOI
Functional bowel disorders and functional abdominal pain.
TL;DR: A committee consensus approach, including criticism from multinational expert reviewers, was used to revise the diagnostic criteria and update diagnosis and treatment recommendations, based on research results.
Book
The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment : A Multinational Consensus
TL;DR: This book presents a single source of standardized definitions, diagnostic criteria and treatment recommendations forFunctional gastrointestinal disorders, which should no longer need to make a diagnosis of exclusion.
Journal ArticleDOI
Design of Treatment Trials for Functional Gastrointestinal Disorders.
E. Jan Irvine,E. Jan Irvine,Jan Tack,Michael D. Crowell,Kok Ann Gwee,Meiyun Ke,Max Schmulson,William E. Whitehead,Brennan Spiegel +8 more
TL;DR: This article summarizes recent progress and regulatory guidance on design of trials to assess the efficacy of new therapies for functional gastrointestinal disorders (FGIDs).
Journal ArticleDOI
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
Charlene M. Prather,Michael Camilleri,Alan R. Zinsmeister,Sanna McKinzie,George M. Thomforde +4 more
TL;DR: Tegaserod accelerates orocecal transit, tends to accelerate colonic transit, and deserves further study in patients with constipation-predominant IBS.
Journal ArticleDOI
Controlled treatment trials in the irritable bowel syndrome: A critique
TL;DR: It is concluded that not a single study offers convincing evidence that any therapy is effective in treating the IBS symptom complex, and well-designed and executed IBS treatment trials are urgently needed.